Mast Cell Tumor in Dogs (Mastocytoma)
- Occurrence: common
- Location of disease: General/Whole body
When to visit the vet?
Non-urgent see a veterinarian within 2–3 days
If the condition worsens / symptoms persist, consult a veterinarian.
Definition
A mastocytoma, also known as a mast cell tumor, is a common form of skin tumor in dogs that arises from mast cells. These cells are part of the immune system and play a role in allergic reactions.
The most important facts at a glance
Mastocytomas, also known as mast cell tumors, are common types of skin cancer in dogs. These tumors arise from mast cells found in connective tissue and play a role in allergic reactions. The exact cause of tumor formation is unclear; however, genetic factors and environmental conditions play a role, especially in breeds such as Boxers and Retrievers. Genetic mutations, particularly in the c-kit gene, lead to uncontrolled cell proliferation and tumor formation.
Symptoms may include movable skin lumps, poorly healing Wounds, and Itching. In severe cases, anorexia and a Tendency to bleed may occur. For diagnosis, fine-needle aspiration is often performed; sometimes a biopsy is required. Treatment usually consists of surgical removal, supplemented as needed by radiation therapy or chemotherapy. Medications such as tyrosine kinase inhibitors help control tumor growth.
The prognosis depends on the tumor grade and the possibility of complete removal. Early detection improves the prognosis. Prevention is difficult because the causes are not fully known; however, regular veterinary examinations help. Research focuses on genetic and molecular mechanisms as well as the development of targeted therapies. Immunotherapy is also being studied to strengthen the immune system to fight Tumors. Overall, research is dynamic and aims to improve prevention, diagnosis, and treatment.
Causes
Mast cells are specialized cells found in the body’s connective tissue, particularly in the skin, airways, and digestive tract. They are known for their role in allergic reactions and immune defense. Mast cells contain granules that can release histamine and heparin when activated.
The exact cause of mast cell tumor development is not fully understood. It is believed that genetic and environmental factors, as well as a combination of both, play a role. Certain dog breeds such as Boxers, Bulldogs, and Retrievers appear to have a genetic predisposition to developing these tumors.
Genetic mutations, particularly in the c-kit gene that encodes the growth factor receptor KIT, are frequently observed in mast cell tumors. These mutations lead to uncontrolled cell proliferation, resulting in tumor formation.
Symptoms
Symptoms of a mastocytoma can vary depending on the location and stage of the tumor. Typically, they appear as skin lumps or masses that can vary in size, shape, and consistency. Some tumors are firm, while others may be soft and movable.
Another common symptom is Itching, as substances released from mast cells can trigger an inflammatory reaction in the skin. In some cases, the tumor may develop ulcers or bleed, especially if it is traumatized.
Systemic symptoms such as Vomiting, Diarrhea, or loss of appetite may occur if the tumor is advanced or has metastasized, particularly to the gastrointestinal tract.
Therapy
Treatment of mast cell tumors can be surgical, medical, or a combination of both. Surgical removal of the tumor is often the first choice, especially for solitary tumors that can be completely removed. The surgeon will attempt to leave a sufficient safety margin around the tumor to ensure complete resection.
In cases where the tumor cannot be completely removed or metastases are present, additional therapy may be necessary. This may include radiation therapy or chemotherapy. Medications such as tyrosine kinase inhibitors (e.g., toceranib or masitinib) can also be used to control tumor growth.
Symptomatic treatments, such as antihistamines to control itching and inflammatory conditions, may also be part of the treatment plan.
Prognosis and follow-up care
The prognosis for dogs with mast cell tumors depends on several factors, including the tumor grade, its location, and the possibility of complete removal. Tumors that are detected early and can be completely removed generally have a good prognosis.
High-grade tumors or metastatic tumors have a poorer prognosis. The histological grade of the tumor, determined by biopsy, is a key factor for prognosis and helps determine the best therapy options.
A multidisciplinary approach combining surgery, radiation therapy, and medical treatment can improve the survival time and quality of life of the affected dog.
Prevention
Because the exact causes of mast cell tumors are not fully understood, there are no specific prevention measures for this condition. Early detection and regular veterinary check-ups are the best strategies to reduce the risk of serious complications.
For dogs prone to mast cell tumors, regular skin examinations by the pet owner can be helpful. Any new or changing skin nodule should be presented to a veterinarian.
A healthy diet and a healthy weight can also contribute to the dog’s overall health, although they do not directly affect the risk of mast cell tumors. Close collaboration with a veterinarian can help identify and manage individual risk factors.
Outlook on current research
Research into mastocytomas in dogs has made significant progress in recent years. Mastocytomas, also known as mast cell tumors, are one of the most common types of skin cancer in dogs. Researchers are focusing on the genetic and molecular mechanisms that contribute to the development of these tumors. An important discovery is the identification of mutations in the c-KIT gene, which have been detected in many mastocytomas. These mutations can promote uncontrolled cell division and tumor formation. The development of targeted therapies that act specifically against these mutations represents a major advance in the treatment of mastocytomas.
Another area of research is the investigation of biomarkers that can help better determine the prognosis for dogs with mastocytomas. Biomarkers are specific molecules that can be measured in blood or tissue and provide clues about the course of the disease. By identifying such biomarkers, researchers hope to develop more individualized treatment plans tailored to the specific needs of each dog.
Immunotherapy is also a promising area of research. This form of therapy aims to strengthen the dog’s immune system to fight tumor cells more effectively. Early studies have shown that certain vaccines and immunomodulatory medications can slow the growth of mastocytomas and, in some cases, even reduce them. However, these treatment approaches are still in the early stages of clinical testing and require further investigation to confirm their effectiveness and safety.
Another area being intensively researched is the role of the tumor microenvironment. The interaction between tumor cells and the surrounding cells and structures can influence tumor growth. Researchers are investigating how changes in this microenvironment can be used to inhibit tumor growth. This could open up new approaches for treating mastocytomas that go beyond directly targeting tumor cells.
In summary, research on mastocytomas in dogs is dynamic and many promising approaches are being pursued. By combining genetic, molecular, immunological, and environmental factors, scientists hope to further improve the prevention, diagnosis, and treatment of this disease.
Frequently Asked Questions (FAQs)
1. What is a mastocytoma?
2. Which dogs are most commonly affected?
3. How do you recognize a mastocytoma in a dog?
4. Is a mastocytoma always malignant?
5. What treatment options are available?
6. What is the prognosis for dogs with mastocytomas?
7. Can mastocytomas be prevented in dogs?
8. Are mastocytomas painful in dogs?
9. How fast do mastocytomas grow?
10. Can a mastocytoma come back after treatment?
Literature
- de Nardi, A. B., Horta, R. S., Fonseca-Alves, C. E., Paiva, F. N., Linhares, L. C. M., Firmo, B. F., Sueiro, F. A. R., Oliveira, K. D., Lourenço, S. V., Strefezzi, R. F., & Dagli, M. L. Z. (2022). Diagnosis, prognosis and treatment of canine cutaneous and subcutaneous mast cell tumors. Cells, 11(4), Article 618. https://doi.org/10.3390/cells11040618
- Blackwood, L., Murphy, S., Buracco, P., De Vos, J. P., De Fornel-Thibaud, P., Hirschberger, J., Kessler, M., Pastor, J., Ponce, F., Savary-Bataille, K., & Argyle, D. J. (2012). European consensus document on mast cell tumours in dogs and cats. Veterinary and Comparative Oncology, 10(3), e1–e29. https://doi.org/10.1111/j.1476-5829.2012.00341.x
- Berlato, D., Bulman-Fleming, J., Clifford, C. A., Garrett, L., Intile, J., Jones, P., Kamstock, D., Liptak, J., Pavuk, A., Powell, R., & Rasotto, R. (2021). Value, limitations, and recommendations for grading of canine cutaneous mast cell tumors: A consensus of the Oncology-Pathology Working Group. Veterinary Pathology, 58(5), 858–863. https://doi.org/10.1177/03009858211009785
- Kiupel, M., Webster, J. D., Bailey, K. L., Best, S., DeLay, J., Detrisac, C. J., Fitzgerald, S. D., Gamble, D., Ginn, P. E., Goldschmidt, M. H., Hendrick, M. J., Howerth, E. W., Janovitz, E. B., Langohr, I., Lenz, S. D., Lipscomb, T. P., Miller, M. A., Misdorp, W., Moroff, S., … Miller, R. (2011). Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Veterinary Pathology, 48(1), 147–155. https://doi.org/10.1177/0300985810386469
- Freytag, J. O., Queiroz, M. R., Govoni, V. M., Pereira, I. V. A., Pulz, L. H., Queiroga, F. L., & Cogliati, B. (2021). Prognostic value of immunohistochemical markers in canine cutaneous mast cell tumours: A systematic review and meta-analysis. Veterinary and Comparative Oncology, 19(3), 529–540. https://doi.org/10.1111/vco.12692
- Garrett, L. D. (2014). Canine mast cell tumors: Diagnosis, treatment, and prognosis. Veterinary Medicine: Research and Reports, 5, 49–58. https://doi.org/10.2147/VMRR.S41005
- Hahn, K. A., Ogilvie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P. S., Kinet, J.-P., & Palmerini, F. (2008). Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine, 22(6), 1301–1309. https://doi.org/10.1111/j.1939-1676.2008.0190.x
- London, C. A., Malpas, P. B., Wood-Follis, S. L., Boucher, J. F., Rusk, A. W., Rosenberg, M. P., Henry, C. J., Mitchener, K. L., Klein, M. K., Hintermeister, J. G., Bergman, P. J., Couto, G. C., Mauldin, G. N., & Michels, G. M. (2009). Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent mast cell tumor following surgical excision. Clinical Cancer Research, 15(11), 3856–3865. https://doi.org/10.1158/1078-0432.CCR-08-1860